medigraphic.com
ISSN 0301-696X (Print)
Órgano de difusión del Servicio de Sanidad Militar y del Colegio Nacional de Médicos Militares

2017, Number 6

<< Back Next >>

Rev Sanid Milit Mex 2017; 71 (6)

Immunological alterations in patients with schizophrenia and Cannabis use

Pantoja-Villagómez D

Language: Spanish
References: 37
Page: 507-513
PDF size: 229.82 Kb.


ABSTRACT

Introduction: Schizophrenia is a chronic and degenerative mental disorder. There is evidence of neuroinflammation in schizophrenia. A9-THC modulates the Th-1/Th-2 balance, inhibits the production of cytokines, chymosins, and the migration of inflammatory cells. Objective: To evaluate and compare the immunological response of patients with schizophrenia with and without Cannabis use through PANSS, FACT-Sz and lymphocyte populations. Material and methods: Patients who attended the INPRFM from April to November 2016. The sample consisted of 23 patients with schizophrenia divided into those with and without Cannabis use. Results: The average age was 33.7 years; 100% were single, on treatment with risperidone or olanzapine, with an average treatment of 26.96 weeks; the mean dose was 145.65 mg equivalent of chlorpromazine; there was an average of 18.26 hrs from their last consumption; their total time of consumption was 169.57 weeks. The patients had a mean of the total PANSS score of 103.4, and a FACT-Sz, of 65.2, with no significant differences. Significant differences were observed in lymphocyte counts in CD3 + CD8 + T lymphocytes and NK cells. Conclusions: Patients present a decrease in CD4 + CD8 + T lymphocytes and an increase in NK cells; the use other substances, psychiatric and medical co-morbidities are common.


REFERENCES

  1. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res. 2010; 121 (1-3): 46-54.

  2. American Psychiatric Association. Guía de consulta de los Criterios Diagnósticos Del DSM-5. American Psychiatric Association; 2014. p. 267.

  3. Lieberman JA, Stroup S, Perkins DO. The American Psychiatric Publishing Textbook Of Schizophrenia. 2006. p. 453.

  4. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994; 89 (5): 346-351.

  5. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011; 70 (7): 663-671.

  6. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Progress Neuropsychopharmacol Biol Psychiatry. 2013; 42: 115-121.

  7. Suárez-Pinilla P, López-Gil J, Crespo-Facorro B. Immune system: a possible nexus between cannabinoids and psychosis. Brain Behav Immun. 2014; 40: 269-282.

  8. Pandey GN, Ren X, Rizavi HS, Zhang H. Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients. Schizophr Res. 2015; 164 (1-3): 193-198.

  9. De Filippis D, D’Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol. 2008; 20 (1): 20-25.

  10. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006; 20 (6): 532-545.

  11. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Muller N. T-and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 2007; 152 (2-3): 173-180.

  12. Ueda Y, Miyagawa N, Wakitani K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci. 2007; 80 (5): 414-419.

  13. Cunha JM, Carlini EA, Pereira E, Ramos OL, Pimentel C, Gagliardi R et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980; 21 (3): 175-185.

  14. D’Souza DC. Cannabinoids and psychosis. EUA: Department of Psychiatry, Yale University School of Medicine; 2016.

  15. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004; 25 (1-2): 14-23.

  16. Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev. 2016; 15 (6): 513-528. doi: 10.1016/j.autrev.2016.02.008

  17. Klein TW, Newton WC, Zhu Daaka YH, Friedman. Delta 9-tetrahidrocannabinol, citoquinas y la inmunidad a Legionella pneumophila. Proc Soc Exp Biol Med. 1995; 209 (3): 205-212.

  18. Watzl B, Scuderi P, Watson RR. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol. 1991; 288: 63-70.

  19. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipidos. 2000; 108: 169-90.

  20. Franco R, Pacheco R, Lluis C, Ahern GP, O’Connell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol. 2007; 28 (9): 400-407.

  21. Kumar RN. Cámaras WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001; 56 (11): 1059-1068.

  22. Lee CY, Wey SP, Liao MH, Hsu WL, Wu HY, Jan TR. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol. 2008; 8 (5) 732-740.

  23. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Movement disorders. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Haworth Press. 2002, pp. 205-214.

  24. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005; (168): 1-51.

  25. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997; 74 (2): 129-180.

  26. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mastcells. J Immunol. 2003; 170 (10): 4953-4962.

  27. Sexton M, Silvestroni A, Möller T, Stella N. Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis. Inflammopharmacology. 2013; 21 (3): 253-259.

  28. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther. 1998; 285 (1): 285-292.

  29. Howlett C, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002; 54 (2): 161-202.

  30. Lee SF, Newton C, Widen R, Friedman H, Klein TW. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cells stimulation. Eur J Pharmacol. 2001; 423 (2-3): 235-241.

  31. Maccarrone M, Lorenzon T, Bari MG, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000; 275 (41): 31938-31945.

  32. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365 (6441): 61-65.

  33. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. Delta (9)-apoptosis tetrahidrocannabinol inducida en el timo y el bazo como un mecanismo de inmunosupresión in vitro e in vivo. J Pharmacol Exp Ther. 2002b: 302 (2): 451-465.

  34. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Corazón Circ Physiol. 2008; 294 (3): H1145-H1155.

  35. Small-Howard MA, Shimoda LM, Adra CN, Turner H. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. J Biochemical J. 2005; 388 (2): 465-473.

  36. Cabral GA, Staab A. Effects on the immune system. Handb Exp Pharmacol. 2005; (168): 385-423.

  37. Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A et al. Novel rating scales for schizophrenia Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res. 2008; 106 (2-3): 328-336.




2020     |     www.medigraphic.com